Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 USD | +0.24% | -36.75% | -17.36% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.36% | 245M | |
+11.29% | 225B | |
+8.76% | 186B | |
+12.90% | 135B | |
+25.95% | 107B | |
+0.15% | 63.56B | |
+11.08% | 51.04B | |
+5.62% | 51.32B | |
+6.28% | 43.3B | |
+4.80% | 36.99B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Lowers Price Target for NeuroPace to $9 From $12, Maintains Underweight Rating